Importantly, we demonstrate that immune pressure against CD19 by CAR-T cells can result either in emergence of a rapidly relapsing leukaemia that has selectively lost the CD19 CAR epitope, as reported in patients following CD19 CAR30, or a lineage-switched leukaemia that results from reprogramming. This evidence concerns the gene CD19 and leukemia.